ReviewPharmaceutical research2009
Inhaled drug delivery for tuberculosis therapy.
Review in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Engineering of OHet72 Nanocrystals into Nanostructured Microparticles for Pulmonary Delivery of a Novel Antitubercular Drug Candidate.Pharmaceutics · 2026Article
- Review
- Inhaled non-viral delivery systems for RNA therapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.Molecular pharmaceutics · 2023Article
- A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.Drug delivery and translational research · 2023Review
- Multi-drug loaded eugenol-based nanoemulsions for enhanced anti-mycobacterial activity.RSC medicinal chemistry · 2023Article
- Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment.Pharmaceutical research · 2022Article
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Advanced therapeutics · 2022Article
- Nano-in-Microparticles for Aerosol Delivery of Antibiotic-Loaded, Fucose-Derivatized, and Macrophage-Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery.Advanced healthcare materials · 2022Article
- LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles.Advances in experimental medicine and biology · 2022Article
- The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.Frontiers in immunology · 2022Review
- Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy.Pharmaceutics · 2021Article
- A triple combination 'nano' dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization.Drug delivery and translational research · 2021Article
- A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers.Carbohydrate polymers · 2020Review
- The Role of Metallic Nanoparticles in Inhibition of Mycobacterium Tuberculosis and Enhances Phagosome Maturation into the Infected Macrophage.Oman medical journal · 2020Review
- Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.Pharmaceutical research · 2019Review
- A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.Journal of pharmaceutical sciences · 2019Article
- Prophylaxis ofAntimicrobial agents and chemotherapy · 2019Article
- Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.Pharmaceutical research · 2019Article
- Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections.Pharmaceutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One third of the world population is infected with tuberculosis (TB), and new infections occur at a rate of one per second. The recent increase in the emergence of drug-resistant strains of Mycobacterium tuberculosis and the dearth of anti-TB drugs is threatening the future containment of TB. New drugs or delivery systems that will stop the spread of TB and slow down or prevent the development of drug-resistant strains are urgently required. One of the reasons for the emergence of drug-resistant strains is the exposure of mycobacteria to sub-therapeutic levels of one or more antibiotics. Lung lesions containing large numbers of bacteria are poorly vascularized and are fortified with thick fibrous tissue; conventional therapy by the oral and parenteral routes may provide sub-therapeutic levels of anti-TB drugs to these highly sequestered organisms. Administering drugs by the pulmonary route to the lungs allows higher drug concentrations in the vicinity of these lesions. Supplementing conventional therapy with inhaled anti-TB therapy may allow therapeutic concentrations of drug to penetrate effectively into lung lesions and treat the resident mycobacteria.
Indexed as
Identifiers
20183916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.